VJHemOnc Podcast
VJHemOnc
The Video Journal of Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and review! For more news visit www.vjhemonc.com
Episodes
Mentioned books
Nov 17, 2023 • 16min
iwNHL 2023 Session III: Recent updates with the use of antibody-drug conjugates in NHL
John Gribben and Laurie Sehn discuss the use of antibody-drug conjugates (ADCs) in NHL. They explore challenges in comparing treatment options, modulation of target antigen, and FDA's changing requirements for drug approval. Recent updates in the use of ADCs, including decreased accelerated approvals and the importance of efficacy and safety, are also highlighted.
Nov 10, 2023 • 13min
MPN diagnosis & treatment: novel agents in PV, clinical guidance for the use of JAK inhibitors & the growing role of combination approaches
Lucia Masarova, MD, discusses novel agents in PV treatment, clinical guidance for JAK inhibitors in MF, and the growing role of combination approaches. Topics include the use of next-generation sequencing in MPN diagnosis, promising agents for ET and pre-fibrotic MF, benefits and considerations of JAK inhibitors, and ongoing Phase 3 studies for combination therapies in MPN.
Nov 3, 2023 • 15min
iwNHL 2023 Session II: The evolving treatment landscape in mantle cell lymphoma
In this podcast, experts Stephen Ansell and Marek Trněný discuss the evolving treatment landscape in mantle cell lymphoma. They explore the impact of stem cell transplants, the emergence of novel therapies, and the importance of maintenance therapy. Different treatment approaches, including CAR T cell therapy, are also discussed along with the potential for cure and long-term survival rates.
Oct 27, 2023 • 14min
iwNHL 2023 Session I: Updates on the biology and treatment of T-cell lymphoma
In this podcast, experts Francine Foss and Laurence de Leval discuss recent updates in the biology and treatment of T-cell lymphoma, including genetic sub-stratification, targeting signaling pathways, the use of animal models, genetic testing, and associations in T-cell lymphoma, and the practical benefits of baseline molecular testing.
Oct 20, 2023 • 15min
iwAL 2023 Session IV: Transplantation and immunotherapies in AML: improving patient outcomes
Charles Craddock and David Sallman discuss transplantation and immunotherapies in AML, focusing on patient eligibility, challenges in CAR-T therapy, targeting pre-transplant minimal residual disease, and improving patient outcomes through DLI and gamma delta T cells. They also explore the design of a randomized study evaluating prophylactic DLI in high-risk AML patients.
Oct 13, 2023 • 11min
Classifying frailty and approaching elderly patients with lymphoma
Challenges of treating elderly patients with lymphoma, importance of classifying frailty, tailoring treatment based on fitness levels, use of steroids and growth factors to improve tolerance, unmet needs and promising strategies for elderly patients with Hodgkin lymphoma
Oct 6, 2023 • 19min
Updates on the diagnosis, risk stratification and treatment of lower-risk MDS
Sanam Loghavi, medical doctor from The University of Texas MD Anderson Cancer Center, discusses updates on the diagnosis, risk stratification, and treatment of lower-risk MDS. Topics include the challenges in managing LR-MDS, the importance of accurate diagnosis and risk stratification using the IPSS-M model, FDA approval of Luspattersept frontline therapy, constructing pathology reports for optimal patient care, and incorporating various diagnostic tools for diagnosing LR-MDS.
Sep 29, 2023 • 10min
iwAL 2023 Session III: The relevance of TP53 mutation in AML
Andrew Wei, an expert in acute myeloid leukemia, discusses the relevance of TP53 mutation in AML. Topics include diagnostic approaches, defining double hit TP53, risk assessment, and potential treatments for P53 mutant AML.
Sep 22, 2023 • 28min
iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more
Experts Naval Daver, MD and Gail Roboz, MD discuss new treatments in AML, focusing on FLT3 inhibitors, novel combinations, and treating relapsed disease. They also explore treatment options, managing patient expectations, and the benefits of HMA in salvage treatment. Additionally, the importance of guilt and Venetoclax for rapid and deep responses in AML patients eligible for transplant is emphasized.
Sep 15, 2023 • 18min
iwAL 2023 Session I: Clonal hematopoiesis in AML, early detection and potential therapeutics
Experts in acute myeloid leukemia (AML) discuss clonal hematopoiesis, early detection, and potential therapeutics. Topics include CRISPR engineering in investigating mutations, hereditary leukemia predispositions, risk stratification of clonal hematopoiesis, intervention with high-risk patients, interactions between somatic and germline variants, and the significance of early detection and targeted treatments for clonal hematopoiesis in AML patients.
